Telik, Inc. (TELK) is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. Telik’s product candidates are: TELINTRA® (TLK199) is in Phase 2 clinical development for myelodysplastic syndrome, and severe chronic idiopathic neutropenia TELCYTA® (TLK286) is a cancer cell-activated chemotherapeutic that has shown clinical activity in Phase …Read More
Delcath (NASDAQ: DCTH) is a development-stage, specialty pharmaceutical and medical device company focused on oncology. Company is researching breakthroughs in regional chemotherapies with the goal of improving clinical outcomes and potentially reducing drug-related adverse events. At glance: Commercial stage company focused on oncology Proprietary CHEMOSAT delivery systems allow unique whole organ therapy for the liver …Read More
Inovio Pharmaceuticals (INO) is a microcap biotech that is attempting to target the large indications of cancers and infectious diseases. The company’s novel pipeline is based on its SynCon® synthetic vaccine development platform. It is currently developing vaccines to address large areas of need, most notably cervical dysplasia/cancer, prostate cancer, hepatitis C virus, HIV, influenza, …Read More
Catalyst Pharmaceutical Partners (NASDAQ: CPRX) stock found a bottom after sell-off (tax-losses) in the mid-December 2012 and now offers a solid trading opportunity. Besides technical analysis, there are more reasons to join this trade: CPRX announced on December 27th that it received a Nasdaq Staff Deficiency Letter for not compliance with the Minimum Bid Price requirement ($1/share) set forth in …Read More
Excerpt from the Bret Jensen’s article at SeekingAlpha Corcept Therapeutics Incorporated (CORT) is a pharmaceutical company that develops and markets drugs for the treatment of severe metabolic and psychiatric disorders. It focuses on disorders that are associated with a steroid hormone called cortisol. 7 reasons CORT is solid speculative play at $1.40 a share: Two …Read More
Biogen (NASDAQ:BIIB) experimental drug for a rare disease that destroys the brain and spinal cord nerve cells failed in a company study. Biogen says it is ending its research program for the drug, dexpramipexole. The medicine was the in the late stages of testing for a treatment of amyotrophic lateral sclerosis, or ALS, which is …Read More
Synergy Pharmaceuticals, Inc. (SGYP) today announced that plecanatide, its investigational oral drug for the treatment of chronic idiopathic constipation (CIC), was well tolerated and met the primary and key secondary endpoints of a Phase IIb/III clinical study. Full study results will be presented at a major scientific meeting this year. The randomized, double-blind, placebo-controlled, repeat-dose, …Read More
Shares of Rockwell Medical (NASDAQ: RMTI) are still on the mend after a brief dip in November 2012 that caused shares to drop as low as $5.18 following the release of mixed third quarter results. While the company was able to report admirable 6% revenue growth (year-over-year), profits were a bit soft as a result …Read More